Human lipoxygenases (LOXs) are a family of iron-containing enzymes involved in catalyzing the oxidation of polyunsaturated fatty acids to provide the corresponding bioactive hydroxyeicosatetraenoic acid (HETE) metabolites. These eicosanoid signaling molecules are involved in a number of physiologic responses such as platelet aggregation, inflammation, and cell proliferation. Platelet-type 12-(S)-LOX (12-LOX) is of particular interest because of its demonstrated role in skin diseases, diabetes, platelet hemostasis, thrombosis, and cancer. Disclosed herein is the identification and medicinal chemistry optimization of a 4-((2-hydroxy-3- methoxybenzyl)amino)benzenesulfonamide-based scaffold. The compounds display nM potency against 12-LOX and excellent selectivity over related lipoxygenases and cyclooxygenases. In addition to possessing favorable ADME properties, the compounds also inhibit PAR-4 induced aggregation and calcium mobilization in human platelets, and reduce 12-HETE in mouse/human beta cells. The compounds can also be used in methods for treating or preventing a 12- lipoxygenase mediated disease or disorder.
人类脂氧合酶(LOXs)是一类含
铁酶的家族,参与催化多不饱和
脂肪酸的氧化,提供相应的
生物活性羟基
二十碳四烯酸(HETE)代谢产物。这些
花生四烯酸信号分子参与许多生理反应,如血小板聚集、炎症和细胞增殖。血小板型12-(S)-LOX(12-LOX)因其在皮肤疾病、糖尿病、血小板止血、血栓形成和癌症中的已知作用而特别引起关注。本文揭示了基于4-((2-羟基-3-
甲氧基苯基)
氨基)苯磺酰胺骨架的鉴定和药物
化学优化。这些化合物对12-LOX具有纳摩尔级的效力,并且对相关的脂氧合酶和环氧合酶具有良好的选择性。除了具有良好的A
DME性质外,这些化合物还可以抑制PAR-4诱导的人类血小板聚集和
钙离子动员,并减少小鼠/人类β细胞中的12-HETE。这些化合物还可以用于治疗或预防12-脂氧合酶介导的疾病或紊乱的方法。